Effects of sugammadex on the incidence of postoperative nausea and vomiting in patients undergoing laparoscopic abdominal surgery

Effects of sugammadex on the incidence of postoperative nausea and vomiting in patients undergoing laparoscopic abdominal surgery: A randomized assignment study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0008895

Enrollment

114

Registered

2023-10-27

Start date

2024-06-25

Completion date

Unknown

Last updated

2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Patients who have consented to participate in the study and are scheduled for elective laparoscopic abdominal surgery will be randomly assigned to two groups: (A) the test group (sugammadex gro

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who are (1) adults aged 20 or older undergoing laparoscopic abdominal surgery through regular procedures at the hospital, (2) adult patients using intravenous patient-controlled analgesia (PCA) after surgery, and (3) able to provide written informed consent to participate in the clinical trial and understand the procedures of this clinical trial.

Exclusion criteria

Exclusion criteria: (1) Smokers (2) Patients with severe bradycardia and uncontrollable arrhythmias (3) Patients who received both sugammadex and neostigmine for neuromuscular blockade reversal at the end of general anesthesia (4) Patients who underwent postoperative mechanical ventilation (5) Patients who underwent reoperation within 48 hours after surgery (6) For patients who underwent reoperation more than 48 hours after the initial surgery, only the first surgery will be included in the study, and subsequent surgeries will be excluded. (7) Patients discharged on the same day as surgery (8) Patients who used neuromuscular blocking agents other than rocuronium during anesthesia induction

Design outcomes

Primary

Measure	Time frame
Occurrence of PONV (Postoperative Nausea and Vomiting) within 2 days after surgery	—

Secondary

Measure	Time frame
Occurrence of PONV (Postoperative Nausea and Vomiting) in the recovery room;The type and total dosage of antiemetics administered up to the second day after surgery;The usage of IV-PCA (Intravenous Patient-Controlled Analgesia) up to 24 hours after surgery;The type and quantity of analgesics used post-surgery;The NRS (Numerical Rating Scale) for surgical site pain up to the second day after surgery;Occurrence of complications rated III or higher according to the Clavien-Dindo classification;Length of hospital stay	—

Measure

Time frame

Occurrence of PONV (Postoperative Nausea and Vomiting) in the recovery room;The type and total dosage of antiemetics administered up to the second day after surgery;The usage of IV-PCA (Intravenous Patient-Controlled Analgesia) up to 24 hours after surgery;The type and quantity of analgesics used post-surgery;The NRS (Numerical Rating Scale) for surgical site pain up to the second day after surgery;Occurrence of complications rated III or higher according to the Clavien-Dindo classification;Length of hospital stay

—

Countries

Korea, Republic of

Contacts

Public ContactKyung Won Shin

Seoul National University Hospital

skwskw1@naver.com+82-2-2072-0586

Outcome results